Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Andrew Stacey, AAPOS 2021: Retinoblastoma Incidence in Europe – Results from 40 European Countries

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 4th 2021

Andrew Stacey (University of Washington and Seattle Children’s Hospital, Seattle, WA, USA) spoke to us about his study on the increased incidence retinoblastoma; an analysis based on results from 40 European countries.

Questions

  1. Could you tell us about your study aims, design and findings? (00:21)
  2. What are the likely reasons for these findings? (02:57)

Speaker Disclosure: Andrew Stacey has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of AAPOS 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup